Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer
Artículo
Acceso abierto
Artículo
DOAJ
Abstract First-line treatment options for patients with metastatic hormone-sensitive prostate cancer (HSPC) are divided into two groups: androgen receptor signaling inhibitor (ARSI)-based doublet therapy and triplet ther...
LCC LCC:Medicine; TENDOlNjaWVuY2U~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access